Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Fenofibrate Lipid Lowering Agent
Abstract
A 53-year-old woman presented with an eruption on her face and body for 2 weeks that had developed first on the face before spreading to the trunk and extremities. There was burning with sunlight exposure. Her medical conditions included diabetes mellitus, vitamin D deficiency, and hyperlipidemia. Her treatment for the past 4 years included metformin, saxagliptin, atorvastatin, vitamin B12, vitamin D, lansoprazole, and aspirin. Because atorvastatin did not control her lipids, fenofibrate was prescribed. At 3 months, she developed photodermatitis on the sun-exposed areas of her skin and also on sun-covered areas of the chest and back. Examination showed facial erythematous scaly plaques and multiple scaly annular erythematous plaques on her trunk and extremities (Figure 1). Methylprednisolone aceponate ointment, pimecrolimus ointment 0.1%, and sunblock were prescribed. Her facial eruption was only minimally lessened, while the dermatitis worsened on the trunk, arms, and legs.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.